Form 4: Amphastar EVP Exercises Options, Sells Shares

Amphastar Pharmaceuticals' Senior EVP, Production Center, Zhou Rong, exercised stock options and immediately sold an equal number of shares for a profit.

Summary

• Zhou Rong, Senior EVP, Production Center at Amphastar Pharmaceuticals, Inc. (AMPH), engaged in a pre-planned transaction under Rule 10b5-1(c).
• On December 17, 2025, Zhou Rong acquired 9,787 shares of common stock by exercising employee stock options at a price of $11.33 per share.
• Immediately following the acquisition on December 17, 2025, Zhou Rong sold 9,787 shares of common stock at a weighted average price of $26.1959 per share.
• The sales occurred in multiple transactions with prices ranging from $25.97 to $26.50.
• Following these transactions, Zhou Rong directly beneficially owns 138,043 shares of common stock.
• The direct beneficial ownership of 138,043 shares includes 545 shares acquired on May 31, 2025, and one share acquired on November 30, 2025, under the Issuer's 2014 Employee Stock Purchase Plan.
• Additionally, Zhou Rong indirectly beneficially owns 99,668 shares through the Zhou Family Trust, for which the reporting person serves as a trustee.
• An additional 5,000 shares are indirectly beneficially owned through the reporting person's spouse.

Sentiment

Score: 6

Explanation: The transaction is neutral to slightly positive. While an executive selling shares can sometimes be viewed negatively, this was an exercise-and-sell transaction of vested options, often done for liquidity or diversification, and was pre-planned under a 10b5-1 plan. The executive still retains a significant direct and indirect stake in the company.

Positives

• The executive exercised options at a significantly lower price ($11.33) than the sale price ($26.1959), indicating a substantial personal profit from vested equity.
• The transaction was conducted under a Rule 10b5-1(c) plan, suggesting a pre-scheduled and orderly approach to managing executive compensation and liquidity.

Negatives

• The executive sold all shares acquired through the option exercise, which means there was no net increase in their direct equity stake in the company from this specific transaction.

Future Outlook

NA

Industry Context

This Form 4 filing details an individual executive's pre-planned stock transactions and does not provide broader industry context or trends. Such transactions are common for executives managing their equity compensation.

Related Party Transactions

• Indirect beneficial ownership of 99,668 shares held by the Zhou Family Trust, for which the reporting person serves as a trustee.
• Indirect beneficial ownership of 5,000 shares held by the reporting person's spouse.

Stakeholder Impact

• Shareholders: The sale of shares by a Senior EVP could be viewed neutrally as it's a common practice for executives to monetize vested options, especially when pre-planned. It does not significantly alter the executive's overall beneficial ownership percentage.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction where an executive exercised vested stock options and immediately sold the acquired shares. Such transactions are common for executive compensation and liquidity purposes and do not inherently signal a change in the company's fundamental outlook or the executive's long-term confidence. The executive retains a substantial direct and indirect beneficial ownership. Therefore, this specific filing alone does not warrant a change from a 'hold' recommendation, as it provides no new material information regarding the company's operational performance or strategic direction.

Keywords

Amphastar Pharmaceuticals, AMPH, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Executive Compensation, Rule 10b5-1